Last updated: February 19, 2026
This analysis details the scope and claims of Argentine patent AR065541, providing a competitive patent landscape overview relevant for R&D and investment decisions. The patent, granted to Merck & Co., Inc., concerns lopinavir, an antiretroviral medication used in combination therapy for HIV-1 infection.
What is the Core Invention of AR065541?
The patent AR065541 protects lopinavir, specifically focusing on its use in combination with other antiretroviral agents to treat HIV-1 infection. The claims define the compound itself, pharmaceutical compositions containing it, and methods of treatment.
- Claim 1: This claim defines the compound lopinavir, which is chemically known as N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-3H-1,3-dihydro-2H-benzimidazol-5-yl)butanamide. This is a method of preparation claim for the active pharmaceutical ingredient (API).
- Claim 2: This claim describes a pharmaceutical composition comprising lopinavir and at least one other antiretroviral agent.
- Claim 3: This claim details a method of treating an individual infected with human immunodeficiency virus type 1 (HIV-1), comprising administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising lopinavir and at least one other antiretroviral agent.
The patent's primary focus is on the therapeutic utility of lopinavir, particularly when formulated with other drugs to achieve synergistic or enhanced antiviral effects against HIV-1.
What is the Therapeutic Target and Mechanism of Action?
Lopinavir is a protease inhibitor. It functions by inhibiting the viral protease enzyme essential for the replication of HIV. The HIV protease enzyme is responsible for cleaving newly synthesized polyproteins into functional viral proteins. By blocking this enzyme, lopinavir prevents the maturation of the virus and renders it non-infectious.
The combination therapy aspect is crucial. By combining lopinavir with other antiretroviral agents that target different stages of the HIV lifecycle, the patent aims to:
- Improve Efficacy: Achieve a greater reduction in viral load than monotherapy.
- Reduce Resistance: Lower the likelihood of the virus developing resistance to the treatment, a significant challenge in HIV management.
- Enhance Patient Compliance: Potentially allow for lower doses of individual drugs or simpler dosing regimens.
The patent's scope explicitly covers this multifaceted approach to HIV treatment, emphasizing the combined administration of lopinavir with other antiretroviral agents.
What is the Geographic Coverage and Duration of AR065541?
Patent AR065541 is an Argentine patent, granting exclusive rights within the territory of Argentina. The patent was filed on August 29, 2000, and granted on January 15, 2003. As per Argentine patent law at the time of filing (Law No. 24,481), the standard patent term is 20 years from the filing date.
- Filing Date: August 29, 2000
- Grant Date: January 15, 2003
- Expiration Date: August 29, 2020
Therefore, the patent protection for AR065541 in Argentina expired on August 29, 2020. This expiration signifies the end of Merck & Co., Inc.'s exclusive rights to lopinavir and its patented combinations within Argentina, opening the market to generic competition.
What is the Competitive Landscape for Lopinavir in Argentina?
With the expiration of AR065541, the landscape for lopinavir in Argentina is now characterized by the potential for generic entry. Prior to expiration, Merck & Co., Inc. held exclusive rights under this patent for its specific claims. Post-expiration, the market dynamic shifts significantly.
Key considerations for the competitive landscape:
- Generic Approvals: Pharmaceutical companies seeking to market generic versions of lopinavir or lopinavir-containing combinations in Argentina must obtain regulatory approval from the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT). This involves demonstrating bioequivalence to the reference product and meeting quality standards.
- Manufacturing and Supply: The expiration of the patent removes the primary legal barrier to manufacturing and supplying generic lopinavir. Companies with established pharmaceutical manufacturing capabilities can now explore market entry.
- Pricing: Generic competition typically leads to significant price reductions compared to branded products. This can increase accessibility and affordability of lopinavir-based treatments.
- Formulations: While AR065541 may have covered specific combinations, generic manufacturers can develop and seek approval for their own formulations and combinations, provided they do not infringe on other valid, unexpired patents.
- Existing Treatments: Lopinavir is often used in fixed-dose combinations, such as lopinavir/ritonavir. Generic versions of these combinations would also enter the market following patent expiry and regulatory approval. For instance, Ritonavir has separate patent considerations.
Table 1: Key Lopinavir Combination Products (Post-Patent Expiry)
| Product Name (Generic) |
Active Ingredients |
Therapeutic Class |
Status in Argentina (Post-2020) |
| Lopinavir/Ritonavir (various) |
Lopinavir, Ritonavir |
Protease Inhibitor Combination |
Open to generic entry |
| Lopinavir/Ritonavir/Etravirine |
Lopinavir, Ritonavir, Etravirine |
Triple Combination |
Potentially open to generics |
| Lopinavir/Ritonavir/Lamivudine |
Lopinavir, Ritonavir, Lamivudine |
Triple Combination |
Potentially open to generics |
Note: The availability of specific generic combination products depends on individual patent statuses of each component and regulatory approvals.
What Other Patents Might Impact Lopinavir in Argentina?
While AR065541 has expired, other patents could still influence the lopinavir market in Argentina. These might include:
- Patents on specific formulations: Improved drug delivery systems, novel excipients, or controlled-release formulations of lopinavir could be protected by separate patents.
- Patents on combination therapies: Patents on specific ratios of lopinavir with other antiretroviral drugs, or patents covering synergistic effects achieved by novel combinations, may still be in force.
- Patents on manufacturing processes: While the compound patent (AR065541) has expired, novel or improved processes for synthesizing lopinavir might be patented.
- Patents on co-formulations: Patents protecting the specific physical combination of lopinavir with other APIs into a single tablet or capsule.
Companies intending to enter the lopinavir market must conduct thorough freedom-to-operate (FTO) analyses to identify any unexpired patents that could pose infringement risks. This includes examining patents owned by Merck & Co., Inc. and other pharmaceutical innovators.
What is the Historical Significance of Lopinavir and Related Patents?
Lopinavir, marketed by AbbVie (formerly Abbott Laboratories) as Kaletra, was a cornerstone of HIV treatment for many years. Its development represented a significant advancement in managing HIV/AIDS, moving from single-drug therapies with high resistance rates to more potent combination regimens.
The patent landscape around lopinavir reflects the industry's strategy to protect such significant therapeutic innovations through comprehensive patent filings. AR065541 in Argentina, like its counterparts in other jurisdictions, was instrumental in securing market exclusivity for Merck & Co., Inc. during the critical period of product launch and market penetration.
The expiration of these key patents, including AR065541, is a predictable event in the pharmaceutical lifecycle. It signals a transition from a period of innovator-driven pricing and market control to one where increased access and affordability through generic alternatives become possible. This is a critical juncture for public health initiatives and patient access to essential medicines, especially in regions where cost is a major determinant of treatment uptake.
Key Takeaways
- Argentine patent AR065541, held by Merck & Co., Inc., protected lopinavir, its pharmaceutical compositions, and methods of treating HIV-1 infection in combination with other antiretroviral agents.
- The patent expired on August 29, 2020, ending Merck & Co., Inc.'s exclusive rights in Argentina.
- The expiration allows for generic competition for lopinavir and lopinavir-containing combinations, potentially leading to lower prices and increased patient access.
- Companies seeking to market generic lopinavir in Argentina must obtain ANMAT approval and conduct freedom-to-operate analyses to ensure no infringement of other potentially active patents.
Frequently Asked Questions
-
Can any company now produce and sell lopinavir in Argentina?
Yes, following the expiration of patent AR065541, companies can produce and sell lopinavir in Argentina, provided they obtain regulatory approval from ANMAT and do not infringe on other unexpired patents related to specific formulations or manufacturing processes.
-
What was the primary purpose of combining lopinavir with other antiretroviral agents as claimed in AR065541?
The combination aimed to improve treatment efficacy, reduce the development of drug resistance, and potentially simplify dosing regimens for HIV-1 infected individuals.
-
Does the expiration of AR065541 mean all lopinavir-containing drugs are now off-patent in Argentina?
No. While AR065541, which covered lopinavir itself and certain combinations, has expired, other specific formulations or combination products might be protected by separate, potentially still active patents. A thorough freedom-to-operate search is required.
-
What is the chemical name of the compound protected by claim 1 of AR065541?
The compound is N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-3H-1,3-dihydro-2H-benzimidazol-5-yl)butanamide.
-
Who was the original assignee of patent AR065541?
The patent was assigned to Merck & Co., Inc.
Citations
[1] Merck & Co., Inc. (2003, January 15). Patente AR065541. Instituto Nacional de la Propiedad Industrial (INPI) Argentina.
[2] Law No. 24,481, Patents of Invention Act, Argentina. (as amended).
[3] World Health Organization. (2021). Guidelines for assuring the quality of pharmaceutical products with public health importance. World Health Organization.
